Valuation: Mylan Inc

Market Cap 19.68B 17.14B 16.22B 14.74B 27.53B 1,884B 27.67B 193B 74.7B 958B 73.91B 72.27B 3,066B P/E 2026 *
55.2x
P/E 2027 * 33.4x
Enterprise Value 31.74B 27.65B 26.16B 23.77B 44.41B 3,040B 44.63B 312B 121B 1,545B 119B 117B 4,945B EV / Sales 2026 *
2.15x
EV / Sales 2027 * 2.04x
Free-Float
91.44%
Yield 2026 *
2.97%
Yield 2027 * 3.05%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.28%+2.62%+51.61%+100.19% 1,027B
+1.10%+1.45%+52.49%+67.37% 651B
+0.58%+3.54%+19.57%+73.56% 467B
+0.33%+5.72%+39.16%+41.07% 350B
+0.22%+3.87%+20.35%+26.47% 268B
+0.50%+6.92%+11.29%+16.69% 257B
+0.91%-0.70%+38.25%+45.67% 205B
+1.24%+2.59%-27.75%-56.40% 190B
+2.17%+4.20%+34.41%+99.41% 187B
Average +0.08%+2.49%+26.60%+46.00% 400.23B
Weighted average by Cap. -0.19%+2.62%+35.37%+62.23%

Financials

2026 *2027 *
Net sales 14.79B 12.88B 12.19B 11.07B 20.69B 1,416B 20.79B 145B 56.14B 720B 55.55B 54.31B 2,304B 15.05B 13.11B 12.41B 11.27B 21.06B 1,442B 21.17B 148B 57.15B 733B 56.55B 55.29B 2,345B
Net income 221M 192M 182M 165M 309M 21.14B 310M 2.17B 838M 10.74B 829M 811M 34.4B 407M 354M 335M 305M 569M 38.96B 572M 3.99B 1.54B 19.8B 1.53B 1.49B 63.38B
Net Debt 12.07B 10.51B 9.95B 9.04B 16.88B 1,155B 16.96B 118B 45.81B 587B 45.32B 44.32B 1,880B 11.08B 9.65B 9.13B 8.3B 15.5B 1,061B 15.58B 109B 42.06B 539B 41.62B 40.69B 1,726B
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!